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ABSTRACT. The aim of this study was to examine the effect of 
polymorphisms in the cytochrome P450 (CYP) 2C19 gene (CYP2C19) 
on the Helicobacter pylori eradication rate in Brazilian patients with 
functional dyspepsia. Adults diagnosed with functional dyspepsia 
based on the ROME III criteria and infected with H. pylori were 
recruited to this study. The patients were subjected to gastrointestinal 
endoscopy and the H. pylori status was defined when both urease test 
and histopathology results were negative or positive. The patients were 
treated with proton pump inhibitor-based triple therapy (omeprazole, 
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amoxicillin, and clarithromycin). CYP2C19*2 and CYP2C19*3 were 
genotyped by polymerase chain reaction-restriction fragment length 
polymorphism. One hundred and forty-eight patients (81.8% women) 
with a mean (± SD) age of 46.1 (12.2) years were included in this 
study. Based on the CYP2C19 genotypes, the patients were classified 
as homozygous extensive metabolizer (HomEM; 67.6%), heterozygous 
extensive metabolizer (HetEM; 26.3%), or poor metabolizer (PM; 6.1%). 
The H. pylori eradication rates in patients with HomEM, HetEM, and 
PM were 85.0, 89.7, and 100.0% (P = 0.376), respectively. The included 
study population comprised a high frequency of patients carrying the 
HomEM genotype. Although the genotypes of CYP2C19 variants were 
not statistically significant, the results of this study suggest a possible 
effect of the PM genotype on the efficacy of H. pylori eradication.
Key words: Cytochrome P450 CYP2C19; Helicobacter pylori eradication; 
Functional dyspepsia; Poor metabolizer genotype
INTRODUCTION
Helicobacter pylori infection is associated with chronic gastritis, peptic ulcer disease, 
mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma (Wotherspoon, 
1998; Marshall and Windsor, 2005; McColl, 2010). The prevalence of H. pylori infection in 
patients with functional dyspepsia (FD) has been reported to be in the range of 40 to 70% 
(Talley, 1994; Egan et al., 2007). The recommended treatment method in such patients is 
the eradication of H. pylori, which could relieve the symptoms of FD and help prevent other 
gastric complications (Mazzoleni et al., 2011; Malfertheiner et al., 2012). Some studies have 
reported a lower H. pylori eradication rate in patients with FD than that in patients with other 
gastric disorders such as peptic ulcer disease (Jones and Lydeard, 1989; Jones et al., 1990).
Dyspepsia is a common complaint in gastroenterology practice, with a prevalence rate 
of ~30% (Tack et al., 2006). Most affected individuals do not have structural or biochemical 
abnormalities that can explain their symptoms and are, therefore, diagnosed with functional or 
non-ulcer dyspepsia (Fuccio et al., 2008). The symptoms have a major impact on the quality of 
life of FD patients, often prompting them to seek medical advice, which represents ~3-4% of 
all general practitioner consultations (Tack et al., 2006). Dyspepsia is also the most common 
source of referrals to gastroenterologists, imposing a huge economic burden on the individual 
and budgets of many countries through decreased work productivity and missed workdays 
(Sander et al., 2011; Matsuhisa and Tsukui, 2014).
The most common therapeutic regimens for the eradication of H. pylori include the 
concomitant use of proton pump inhibitors (PPIs) and antibiotic agents, resulting in eradication 
rates of 80 to 90% (Tang et al., 2013). PPIs are mostly metabolized by the cytochrome P450 
(CYP) enzyme system, particularly the CYP2C19 enzyme (Ishizaki and Horai, 1999). The 
CYP2C19 gene is highly polymorphic, with several functional polymorphisms or alleles that 
can influence the pharmacokinetics and pharmacodynamics of PPIs (Furuta et al., 2005). The 
wild-type allele, CYP2C19*1, translates into an enzyme with high activity. CYP2C19*2 and 
CYP2C19*3, however, are the most commonly reported alleles and may be involved in inter-
individual variability of drug metabolism (Hunfeld et al., 2010).
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CYP2C19*2 (rs4244285) is a defective allele that carries a single nucleotide 
polymorphism (681G→A) in exon 5, resulting in an aberrant splice site. CYP2C19*3 (rs4986893) 
undergoes a G-to-A transition (636G→A) in exon 4, leading to a premature stop codon. These 
mutations encode a non-functional protein, dramatically decreasing drug metabolism (De Morais 
et al., 1994a,b; Hirota et al., 2013). The CYP2C19 phenotype can be categorized as extensive 
metabolizer (EM) or poor metabolizer (PM) (Ishizaki and Horai, 1999). The homozygous EM 
(HomEM) has two wild-type alleles (*1/*1) that have a functional enzyme, thereby accelerating 
the PPI metabolism. The heterozygous EM (HetEM) genotype carries one wild-type allele and 
one loss-of-function variant allele (*1/*2 or *1/*3), translating into an enzyme with intermediate 
functional capacity. The PM genotype comprises two loss-of-function variant alleles (*2/*2, 
*2/*3, or *3/*3) (Padol et al., 2006); therefore, individuals with the PM genotypes display a 
much slower PPI metabolism rate. This leads to higher PPI bioavailability (approximately 13 
higher than that seen in HomEM individuals) (Furuta et al., 2005).
The aim of this study was to examine the prevalence of the CYP2C19 variant 
genotypes and their influence on the H. pylori eradication rate in patients with FD treated with 
clarithromycin, amoxicillin, and omeprazole for 10 days.
MATERIAL AND METHODS
Patients
Patients with FD were selected for this study from the sample population included 
in the Helicobacter Eradication Relief of Dyspeptic Symptoms Trial (HEROES Trial, 
ClinicalTrials.gov No. NCT00404534). The HEROES Trial is a randomized double-blind, 
placebo-controlled clinical trial carried out at Hospital de Clínicas de Porto Alegre, Porto 
Alegre, Brazil (Mazzoleni et al., 2011). Briefly, community and primary care patients of 
either gender who were 18 years of age or older diagnosed with FD according to the Roma 
III criteria (Fuccio et al., 2008), and who tested positive for H. pylori by histological and 
biochemical diagnostic tests were enrolled in the trial. Patients who had used antibiotics 
or bismuth 4 weeks before enrollment, PPIs 2 weeks before enrollment, or those treated 
with histamine-2 receptor blockers in the week before enrollment were excluded. The 
complete exclusion criteria have been described in detail elsewhere (Mazzoleni et al., 
2011).
Upper gastrointestinal endoscopies were performed at screening and at least 12 
months after screening. Three biopsy specimens were obtained from the body of the 
stomach, three from the antrum, and two from the incisura angularis. The H. pylori status 
was defined when the results of both the urease test and histopathological examination 
were negative or positive for infection (stains: Giemsa and hematoxylin-eosin). A third 
pathologist was consulted in case of disagreement between the primary pathologists.
Eligible patients enrolled in the HEROES Trial were randomly assigned to receive 
the omeprazole (20 mg twice daily), amoxicillin (1000 mg twice daily), and clarithromycin 
(500 mg twice daily) (Omepramix®; Aché Laboratórios Farmacêuticos SA, São Paulo, SP, 
Brazil) treatment for 10 days (antibiotics group) or omeprazole (20 mg twice daily) and 
placebo antibiotic (control group) treatment. Adherence to study medication was assessed 
by the pill count of returned medication. Patients were considered to be adherent if at least 
80% of the prescribed medications for H. pylori eradication were consumed.
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In this study, we examined the prevalence of CYP2C19 variants and their role in H. 
pylori eradication rate in patients belonging to the antibiotics group. Patients who agreed to 
participate in genetic studies were included in this study. DNA was extracted from the stored 
blood samples for subsequent analysis of CYP2C19 polymorphisms. The study protocol was 
approved by the local Institutional Review Board and informed consent was obtained from all 
patients prior to enrollment.
Genetic analysis
Genomic DNA was extracted from blood samples using a salting-out method (Lahiri 
and Nurnberger, 1991). The variant genotypes of the CYP2C19*2 (681G→A; rs4244285) 
and CYP2C19*3 (636G→A; rs4986893) polymorphisms were detected by polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP), using previously described 
primers and conditions (De Morais et al., 1994a,b; Kubota et al., 1996). The amplified 168-bp 
(for CYP2C19*2) and 119-bp (for CYP2C19*3) PCR products were digested with MspI and 
BamHI restriction endonucleases, respectively, and subsequently separated and analyzed in 
10% polyacrylamide gels stained with silver nitrate.
Patients were classified according to their CYP2C19 genotypes, as follows: HomEM, 
homozygous for the wild-type allele (CYP2C19*1/CYP2C19*1); HetEM, heterozygous for 
CYP2C19*2 or CYP2C19*3 (CYP2C19*1/CYP2C19*2 or CYP2C19*1/CYP2C19*3); and 
PM, homozygous for CYP2C19*2 or CYP2C19*3 or compound heterozygous (CYP2C19*2/
CYP2C19*2 or CYP2C19*3/CYP2C19*3 or CYP2C19*2/CYP2C19*3).
Statistical analysis
Allele frequencies were determined by direct count of alleles, and deviations from 
Hardy-Weinberg equilibrium were evaluated by the chi-square test. Associations between 
categorical variables were tested using the chi-square or Fisher exact tests. Continuous 
variables were analyzed by the Student t-test or Mann-Whitney U test. Data analysis was 
conducted using SPSS v.18.0 (SPSS Inc., Chicago, IL, USA). A two-tailed P value < 0.05 was 
considered statistically significant.
RESULTS
A total of 404 patients were recruited for the intention-to-treat analysis in the HEROES 
Trial. Of these, 303 patients consented to participate in genetic studies (154 in the control 
group and 149 in the antibiotics group). One patient in the antibiotics group was lost to follow-
up (Figure 1) because of missing data.
In this study, we analyzed 148 H. pylori-positive patients with FD (121 women, 
81.8%; 27 men, 19.2%) with a mean (SD) age of 46.1 (12.2) years. All patients completed 
the study; the adherence to study medication was 94.6%. The baseline characteristics of the 
included patients are shown in Table 1.
Of the 148 patients, 100 (67.6%) had the HomEM genotype, 39 (26.3%) had the 
HetEM genotype, and 9 (6.1%) had the PM genotype. The overall H. pylori-eradication rate 
was 129/148 (87.2%). The H. pylori-eradication rates in the HomEM, HetEM, and PM groups 
were 85.0, 89.7, and 100.0%, respectively (P = 0.376) (Table 2).
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Figure 1. Flow chart depicting study participants.
Table 1. Baseline characteristics of patients with functional dyspepsia (N = 148).
Variable N (%) 
Age (mean ± SD, years) 46.1 ± 12.2 
Female 121 (81.8) 
Caucasian ethnicity 117 (79.1) 
Education 
10 years 89 (60.2) 
>10 years 59 (39.8) 
Smoking status 
Never smoked 85 (57.4) 
Former 36 (24.3) 
Current 27 (18.2) 
Alcohol consumption 
No consumption 127 (85.8) 
Former 4 (2.7) 
Current 17 (11.5) 
Coffee drinker 98 (66.2) 
 
Table 2. Genotype frequencies of patients stratified by Helicobacter pylori status post-treatment.
1HomEM = homozygous extensive metabolizer; HetEM = heterozygous extensive metabolizer; PM = homozygous 
poor metabolizer.
Genotype1 Total (N = 148) H. pylori-negative (N = 129) H. pylori-positive (N = 19) P 
HomEM 100 (67.6) 85 (85.0) 15 (15.0) 0.376 
HetEM 39 (26.3) 35 (89.7) 4 (10.3)  
PM 9 (6.1) 9 (100.0) -  
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DISCUSSION
In this study, we analyzed patients with FD to investigate the influence of the 
CYP2C19 genotypes on H. pylori eradication rate. We observed a high frequency of the 
HomEM genotype (followed by HetEM) and a low frequency of the PM genotype. H. pylori 
was eradicated in all PM patients, and the success rate of H. pylori treatment was slightly 
higher in patients with HetEM than that in patients with the HomEM genotype. However, the 
differences in eradication rates between CYP2C19 genotypes were not statistically significant.
A major strength of this study is that the study population was a well-selected group 
of patients with FD (diagnosed according to the ROME III criteria) who were positive for 
H. pylori infection. All patients underwent upper gastrointestinal endoscopy with gastric and 
duodenal biopsies, and only those who tested positive for H. pylori were recruited to the 
trial. The infection status was rigorously assessed by two pathologists based on the results 
of the urease test and histopathological examinations; a third pathologist was consulted in 
case of disagreement. All patients received daily doses of clarithromycin, amoxicillin, and 
omeprazole (twice each) for 10 days. This treatment period, longer than the usual 7-day 
treatment period, was chosen because H. pylori eradication is less effective in patients with FD 
than that in patients with other gastric disorders. Additional strengths of this study were that 
only one patient was not followed-up and high proportion of adherence to study medication 
was achieved for all participants.
CYP2C19 is an enzyme involved in the metabolism of several clinically used drugs, 
including some barbiturates, diazepam, proguanil, propranolol, and clopidogrel (Hirota et al., 
2013; Liboredo and Pena, 2014). This enzyme is also responsible for the in vivo metabolism 
of most PPIs, such as omeprazole, lansoprazole, and pantoprazole (Ishizaki and Horai, 1999; 
Furuta et al., 2005). Genetic polymorphisms in CYP2C19 are associated with increased clinical 
efficacy of PPI-based triple therapies for H. pylori eradication, and they could also be of clinical 
concern in the treatment of acid-related diseases with PPIs (Ishizaki and Horai, 1999; Zhao 
et al., 2008). It is known that the rate of PPI clearance (from the circulation) in individuals 
expressing the PM genotype is slower than that in individuals expressing the HomEM or 
HetEM genotypes (Zhao et al., 2008; Lee et al., 2014). Studies on the pharmacogenetics, 
pharmacodynamics, and pharmacokinetics of PPIs have shown that the plasma omeprazole 
concentrations in patients receiving a single dose of omeprazole differed between those 
carrying the three different genotype of CYP2C19. Plasma omeprazole levels in individuals 
with the PM genotype are sustained long after drug administration. Furthermore, the mean 
values of the areas under the plasma omeprazole concentration-time curves in the PM group 
are ~13 times higher than those in the HomEM group (Furuta et al., 2005).
The CYP2C19 genotype frequencies observed in our study are consistent with those of 
previous studies in Brazilian populations (Suarez-Kurtz et al., 2012). A recent study conducted 
in Southern Brazil (at the same geographic location sampled in this study) reported HomEM, 
HetEM, and PM genotype frequencies of 71.5, 26.3, and 2.2%, respectively (Kohlrausch et al., 
2014). Other studies conducted in western populations have also reported similar CYP2C19 
genotype distributions (Ishizaki and Horai, 1999; Kurose et al., 2012; Nastasi-Catanese et 
al., 2013). However, a significantly different distribution was reported in Asian populations, 
where the frequency of the PM genotype was ~23% higher than that in western populations 
(approximately 5%) (Ishizaki and Horai, 1999; Hirota et al., 2013).
Studies evaluating CYP2C19 variants and H. pylori eradication in omeprazole-based 
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regimens have shown conflicting results. While some studies have reported a significant 
association between H. pylori cure rates and CYP2C19 genotypes (Sheu et al., 2005; Sugimoto 
et al., 2006; Chaudhry et al., 2009), others have been unable to statistically confirm the 
association between the CYP2C19 genotypes and successful H. pylori eradication; however, 
the latter studies have reported a high H. pylori eradication rate in individuals carrying the 
PM genotype, compared to those carrying the EM genotype (Inaba et al., 2002; Sapone et al., 
2003; Zhang et al., 2010). These results are similar to the results seen in our sample population; 
that is, bacteria were eradicated in all (100%) individuals carrying the PM genotype, although 
statistical significance was not achieved. It is worth noting that several meta-analyses have 
reported a significant association between the CYP2C19 genotypes and H. pylori eradication 
rates (Padol et al., 2006; Zhao et al., 2008; Tang et al., 2013).
PPI, clarithromycin, and amoxicillin or metronidazole triple therapy has been the 
universally recommended treatment method for H. pylori-infection, since its proposal at the 
First Maastricht conference (Malfertheiner et al., 1997). Recent studies have indicated the 
decreased efficacy of this combination over the years, resulting H. pylori-eradication rates of 
<70% (Malfertheiner et al., 2012). The reduced efficacy of standard triple therapy has been 
attributed to antibiotic resistance (Furuta et al., 2005; Lee et al., 2014). Recent years have seen 
the emergence of a few amoxicillin-resistant H. pylori strains; however, the major limiting factor 
of PPI-amoxicillin-clarithromycin triple therapy is the resistance of recent H. pylori strains to 
clarithromycin (Furuta et al., 2005). H. pylori shows varied antibiotic susceptibility patterns in 
various geographical locations; moreover, this bacterium has been substantially influenced by 
the prior use of these drugs (Han et al., 1999). Previous studies conducted in Brazil have reported 
varying rates of H. pylori resistance to clarithromycin, ranging from 11.1 to 17.3% (Prazeres 
Magalhães et al., 2002; Eisig et al., 2011; Picoli et al., 2014). In this study, we could not show an 
association between the CYP2C19 genotype and efficacy of H. pylori eradication; however, H. 
pylori eradication was observed in a large proportion of patients (87.2%). This may be attributed 
to the low rates of clarithromycin resistance in H. pylori strains in Brazil, as well as the high 
patient compliance and prolonged treatment time of this study.
The results of this study are subject to certain limitations. The statistical power to 
detect differences was limited by the small sample size and low frequency of individuals 
carrying the PM genotype. Additionally, the CYP2C19 gene shows great variability, with more 
than 30 alleles being identified, some of which have been classified as ultrarapid metabolizers 
(CYP2C19*17). This increases the complexity of genotype-phenotype studies investigating the 
CYP2C19 gene. In this study, the most commonly reported CYP2C19 variants were analyzed.
In conclusion, no association was found between the CYP2C19 genotype variants and H. 
pylori eradication rates. However, the results suggest a possible role of the PM genotype in determining 
the efficacy of H. pylori eradication. Therefore, we suggest that the dosage of PPI (in triple therapy) 
could be increased in populations with a high frequency of individuals carrying the EM genotype.
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